New research has shown that adjuvant combination radio / hormone replacement therapy may improve survival in patients with prostate cancer having a high Gleason score (9-10 points) until relapse.
Doctors often hesitant to treat patients with prostate cancer after surgery and to relapse, since it can not only benefit, but also cause side effects. However, in the case of treatment carried out aggressive prostate cancer is necessary.
Patients with aggressive forms of prostate cancer frequently suffer from a relapse - a disease returns to 80% of patients during the first five years after surgery and 90% for the first ten years after surgery.
In the new study, the researchers examined data on 639 men (mean age 66 years) with prostate cancer between 1999 and 2013. Tumors were assessed by Gleason and was rated 9-10. Of these, 559 people received radical prostatectomy, adjuvant. external radiotherapy and androgen-deprivation therapy MaxRP, and lymph node dissection. The other 80 men were held remote radiotherapy, brachytherapy and androgen-deprivation therapy called MaxRT.
The median follow up of patients was 4.78 years for men who were treated with MaxR, and 5.51 years for men who were treated with MaxRT. Overall, 161 (25.1%) participant had died, including 106 (65.8%) of prostate cancer.
It found no significant difference in the risk of death from prostate cancer or death from all causes among those who took MaxRP and MaxRT. This indicates that treatment MaxRP or MaxRT men with aggressive prostate cancer leads to an equivalent risk of mortality.
Scientists also said that holding the only surgery to remove prostate cancer with an estimate of 9-10 Gleason leads to the death of 20% of cancer patients in five years, while this number can be reduced to less than 10% for the appropriate use of low-dose radiation and hormone therapy after surgery and to increase the level of PSA, testifying about relapse.